信迪利单抗联合长春瑞滨及顺铂化疗方案治疗晚期非小细胞肺癌的临床效果  

Clinical efficacy of Sintilimab combined with vinorelbine and cisplatin chemotherapy in treatment of advanced non-small cell lung cancer

作　　者：王粉[1] 杜凯 刘钰 WANG Fen;DU Kai;LIU Yu(Department of Oncology,the First People's Hospital of Pingdingshan,Pingdingshan,Henan 467000,China)

机构地区：[1]平顶山市第一人民医院肿瘤科,河南平顶山467000

出　　处：《医药论坛杂志》2024年第11期1204-1207,1212,共5页Journal of Medical Forum

摘　　要：目的观察信迪利单抗联合长春瑞滨及顺铂化疗方案对晚期非小细胞肺癌患者预后的影响。方法采用前瞻性随机对照研究,选择2020年1月—2021年12月平顶山市第一人民医院收治的晚期非小细胞肺癌患者作为研究对象,经随机数字表法分为两组,对照组采用长春瑞滨及顺铂化疗方案,观察组采用信迪利单抗联合长春瑞滨及顺铂化疗方案。比较患者临床疗效、预后情况、血清肿瘤标志物水平[癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白21-1片段(CYFRA21-1)]、免疫功能[白细胞分化抗原3(CD3^(+))、白细胞分化抗原4(CD4^(+))、白细胞分化抗原8(CD8^(+))]以及用药毒副反应情况。结果与对照组相比,观察组客观缓解率(ORR)、疾病控制率(DCR)更高,且1年后生存率和平均生存时间更高(P<0.05)。治疗后,观察组血清肿瘤标志物水平低于对照组,免疫功能改善优于对照组(P<0.05)。两组毒副反应比较差异无统计学意义(P>0.05)。结论信迪利单抗联合长春瑞滨及顺铂化疗方案可以有效提高晚期非小细胞肺癌患者临床疗效,延长生存期,改善免疫功能,安全性较好。Objective To observe the effect of Sintilimab combined with vinorelbine+cisplatin chemotherapy on the prognosis of patients with advanced non-small cell lung cancer.Methods A prospective randomized controlled study was conducted,selecting patients with advanced non-small cell lung cancer admitted to the First People's Hospital of Pingdingshan from January 2020 to December 2021 as the study subjects.They were divided into two groups using a random number table method.The control group was treated with changchun vinorelbine+cisplatin chemotherapy,and the observation group was treated with Sintilimab plus changchun vinorelbine+cisplatin chemotherapy.The clinical efficacy,prognosis,serum tumor marker levels[Carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cell Keratin 21-1 fragment(CYFRA21-1)],immune function(CD3^(+),CD4^(+),CD8^(+)),and toxic side effects of drugs were compared.Results Compared with the control group,the observation group had higher objective response rate(ORR),disease control rate(DCR),and higher 1-year survival rate and average survival time(P<0.05).After treatment,the serum tumor marker levels in the observation group were lower than those of the control group,and the improvement of immune function was better than that of the control group(P<0.05).There was no significant difference in the toxic side effects between the two groups(P>0.05).Conclusion Sintilimab combined with vinorelbine+cisplatin chemotherapy regimen can effectively improve the clinical efficacy,prolong the survival period,improve immune function,and have better safety in patients with advanced non-small cell lung cancer.

关 键 词：非小细胞肺癌 晚期 信迪利单抗 长春瑞滨 顺铂 生存 

分 类 号：R734.2[医药卫生—肿瘤]